[CAS NO. 738-70-5] Trimethoprim

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [738-70-5]

Catalog

HY-B0510

Brand

MCE

CAS

738-70-5

DESCRIPTION [738-70-5]

Overview

MDL	MFCD00036761
Molecular Weight	290.32
Molecular Formula	C14H18N4O3
SMILES	NC1=NC=C(CC2=CC(OC)=C(OC)C(OC)=C2)C(N)=N1

For research use only. We do not sell to patients.

3 Publications Citing Use of MCE

Summary

Trimethoprim is a bacteriostatic antibiotic and an orally active dihydrofolate reductase inhibitor. Trimethoprim is active against a wide range of Gram-positive and Gram-negative aerobic bacteria . Trimethoprim has the potential for the research of urinary tract infections, Shigellosis and Pneumocystis pneumonia. Trimethoprim can inhibit infection of Influenza A virus in chick embryo when combinated with zinc ^[1] ^[2] ^[3] ^[4] .

IC50 & Target

Dihydrofolate reductase, Bacteria ^[1]
Influenza A virus ^[4]

In Vitro

Trimethoprim interrupts folate metabolism by inhibition of the activity of dihydrofolase reductase (DHFR), which reduces dihydrofolate to tetrahydrofolate (THF) ^[1] .
Trimethoprim (3 μg/mL; 1 h) induces protein aggregation and main heat shock proteins (Hsps) in E. coli cells, which indicates that Trimethoprim sulfate presence leads to protein misfolding ^[1] .
Trimethoprim (1.5-3 μg/mL; 1 h) causes induction of DnaK, DnaJ, GroEL, ClpB, and IbpA/B Hsps in E. coli cells exposed to folate and heat stress ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Trimethoprim (10 mg/kg; i.v.; once every 12 h; 3 d) shows antibacterial activity against H. influenzae , S. pneumoniae , E. coli and N. meningitidis in infected mice ^[2] .
Trimethoprim can be connected with the thiomaltose (TM-TMP) and shows stability with a half-life of about 1 hour in complete serum, and has an MIC value around 1 μM against E. coli ^[2] .
Trimethoprim (10 mg/mL; 0.5 mL; inject with Trimethoprim-Zn combined suspension) decreases the virus titer and increases the survival rate of chicken embryo ^[4] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female C3H/HeOuJ mice (transurethrally infected with a 50 μL suspension containing 1-2×10 ⁷ CFU of E. coli under 3% isoflurane) ^[2]
Dosage:	10 mg/kg
Administration:	i.v.; once every 12 h; for 3 d
Result:	Showed antibacterial activity against H. influenzae , S. pneumoniae , E. coli and N. meningitidis with CD ₅₀ s of 150 mg/kg, 335 mg/kg, 27.5 mg/kg and 8.4 mg/kg, respectively in infected mice.

Animal Model:	Fertilized eggs (injected H3N2 virus into amniotic and allantoic space at day 8) ^[4]
Dosage:	10 mg/mL; 0.5 mL
Administration:	The Trimethoprim-Zn combined suspension was injected into the air sac; single dosage
Result:	Decreased the virus titer and increased the survival rate of chicken embryo. The survival rate peaked at ratio about 0.18 (Zn/Trimethoprim).

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT01757236	University Hospital, Tours\|Pfizer\|International Clinical Trials Association	Hip Prosthetic Joint Infection	October 2012	Phase 2
NCT00869518	University of California, San Francisco	Staphylococcus Aureus\|HIV Infections	July 2009	Phase 2
NCT02188472	Henrik Enghusen Poulsen\|Klinisk Biokemisk Afdeling\|Klinisk farmakologisk Afdeling\|Sektion for Biomedicin Institut for Veterinær Patobiologi\|Rigshospitalet, Denmark	Oxidative Stress	November 2010	Phase 1
NCT00002002	Lederle Laboratories\|NIH AIDS Clinical Trials Information Service	Pneumonia, Pneumocystis Carinii\|HIV Infections		Not Applicable
NCT00002283	Jacobus Pharmaceutical\|NIH AIDS Clinical Trials Information Service	Pneumonia, Pneumocystis Carinii\|HIV Infections		Not Applicable
NCT02371603	GlaxoSmithKline	Anaemia	February 11, 2015	Phase 1
NCT00141037	National Institute of Allergy and Infectious Diseases (NIAID)\|Astellas Pharma Inc\|Hoffmann-La Roche	Kidney Diseases\|Kidney Transplantation\|Kidney Transplant\|Renal Transplantation\|Renal Transplant	March 2004	Phase 1\|Phase 2
NCT00014911	National Institute of Allergy and Infectious Diseases (NIAID)\|Immune Tolerance Network (ITN)	Diabetes Mellitus, Insulin-Dependent	April 2001	Phase 2
NCT03077711	NorthShore University HealthSystem	Urinary Tract Infections, Recurrent	June 2016	Phase 4
NCT05268120	Leiden University Medical Center	MRSA	July 25, 2022	Not Applicable
NCT00078559	University of Wisconsin, Madison\|Immune Tolerance Network (ITN)	Kidney Transplantation\|Kidney Disease	November 2003	Phase 1\|Phase 2
NCT03489629	University of North Carolina, Chapel Hill\|University of Washington\|Cook Children´s Medical Center\|Indiana University\|University of Michigan\|University of Texas Southwestern Medical Center\|St. Louis Children´s Hospital	Cystic Fibrosis	April 3, 2018	Phase 2
NCT02879981	Hoffmann-La Roche	Bronchitis	November 10, 2016
NCT03746106	University of California, San Francisco\|Tufts University\|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)\|University of California, Davis	Vitamin B1 Deficiency\|Thiamine Deficiency	January 28, 2019	Phase 4
NCT01820897	JOSE MANUEL ARREOLA GUERRA\|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran	Urinary Tract Infection\|Asymptomatic Bacteriuria\|Allograft Rejection\|Microbiologic Resistance\|Hospitalization	April 2013	Phase 4
NCT04306731	University of Sulaimani	Recurrent Urinary Tract Infection	September 20, 2014	Not Applicable
NCT00380640	The Hospital for Sick Children	Epidermolysis Bullosa	September 2006	Phase 2
NCT05418777	William Beaumont Hospitals	COPD Exacerbation Acute	September 28, 2022	Phase 1\|Phase 2
NCT00752375	University of Alberta\|Canadian Urological Association	Pyelonephritis	February 2009	Phase 3
NCT05398679	Fundacion Clinic per a la Recerca Biomédica	Endocarditis Infective	June 1, 2022	Phase 4
NCT05274672	Baylor Research Institute\|Albert Einstein Healthcare Network	Benign Prostatic Hyperplasia\|Urinary Tract Infections	March 1, 2022	Phase 4
NCT01137903	Universidad Complutense de Madrid	Osteomyelitis\|Diabetic Foot\|Diabetic Foot Ulcers	April 2010	Not Applicable
NCT03173053	Radboud University Medical Center\|ZonMw: The Netherlands Organisation for Health Research and Development\|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)\|University College, London	Staphylococcus Aureus\|Motility Disorder	February 8, 2018	Not Applicable
NCT01140516	McMaster University\|The Physicians´ Services Incorporated Foundation\|Hamilton Health Sciences Corporation\|McMaster Surgical Associates	Hydronephrosis\|Urinary Tract Infection	July 2010	Not Applicable
NCT02902640	Hoffmann-La Roche	Bronchitis	November 15, 2016
NCT00002120	U.S. Bioscience\|Jacobus Pharmaceutical\|NIH AIDS Clinical Trials Information Service	Pneumonia, Pneumocystis Carinii\|HIV Infections		Phase 1
NCT03235947	Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran\|Laboratorios Senosiain, S.A. de C.V.	Urinary Tract Infection\|Asymptomatic Bacteriuria	September 7, 2016	Phase 4
NCT00002850	Gary Morrow\|National Cancer Institute (NCI)\|Eastern Cooperative Oncology Group\|University of Rochester	Infection\|Multiple Myeloma	March 1997	Phase 3
NCT03919435	University of Pennsylvania	Granulomatosis With Polyangiitis\|Wegener Granulomatosis	March 27, 2019	Phase 1\|Phase 2
NCT01507974	HaEmek Medical Center, Israel	Pregnancy Complications	January 16, 2012	Not Applicable
NCT02145338	Newcastle-upon-Tyne Hospitals NHS Trust\|NHS Health Technology Assessment Programme\|Newcastle University\|Glasgow Caledonian University\|University of Aberdeen\|Cambridge University Hospitals NHS Foundation Trust\|North Bristol NHS Trust\|University of Southampton	Urinary Tract Infections, Recurrent	September 2013	Phase 4

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL ( 172.22 mM ; Need ultrasonic)

H ₂ O : 0.67 mg/mL ( 2.31 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.4445 mL	17.2224 mL	34.4447 mL
5 mM	0.6889 mL	3.4445 mL	6.8889 mL
10 mM	0.3444 mL	1.7222 mL	3.4445 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.5 mg/mL (8.61 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (8.61 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.5 mg/mL (8.61 mM); Clear solution

* All of the co-solvents are available by MCE.

References

Synonyms

2,4-Pyrimidinediamine, 5-[(3,4,5-trimethoxyphenyl)methyl]-

Pyrimidine, 2,4-diamino-5-(3,4,5-trimethoxybenzyl)-

5-[(3,4,5-Trimethoxyphenyl)methyl]-2,4-pyrimidinediamine

BW 56-72

2,4-Diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine

Syraprim

Trimethoprim

NIH 204

2,4-Diamino-5-(3′,4′,5′-trimethoxybenzyl)pyrimidine

Trimethioprim

Trimetoprim

Triprim

Trimpex

Trimanyl

Instalac

Trimogal

Wellcoprim

Monotrim

Proloprim

Tiempe

Trimopan

Uretrim

NSC 106568

Infectotrimet